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Background: About 3885 women are diagnosed with breast cancer and 1285 die from the disease each year in Bulgaria.
However no genetic testing to identify the mutations in high-risk families has been provided so far.
Methods: We evaluated 200 Bulgarian women with primary invasive breast cancer and with personal/ family history of
breast cancer for the presence of unequivocally damaging germline mutations in BRCA1/2 using
Sanger sequencing.
Results: Of the 200 patients, 39 (19.5 %) carried a disease predisposing mutation, including 28 (14 %) with a BRCA1
mutation and 11 (5.5 %) with a BRCA2 mutation. At BRCA1, 6 different mutations were identified, including 2 frameshifts, 1
nonsense and 1 missense that had been previously reported (c.5030_5033delCTAA, c.5263_5264insC, c.4603G > T,
c.181 T > G), and 2 frameshifts, which were novel to this study (c.464delA, c.5397_5403delCCCTTGG).
At BRCA2, 7 different frameshift mutations were identified, including 5 previously reported (5851_5854delAGTT,
c.5946delT, c.5718_5719delCT, c.7910_7914delCCTTT,c.9098_9099insA) and 2 novel (c.8532_8533delAA, c.9682delA).
A BRCA1 mutation was found in 18.4 % of women diagnosed with breast cancer at/or under the age of 40 compared to
11.2 % of women diagnosed at a later age; a BRCA2 mutation was found in 4 % of women diagnosed at/or under the
age of 40 compared to 6.5 % of women diagnosed at a later age. A mutation was present in 26.8 % patients
with a positive family history and in 14.4 % of women with a negative family history.
The most prevalent mutation observed in 22 patients (11 %) was BRCA1 c.5263_5264insC, a known Slavic
mutation with founder effect in Eastern European and AJ communities. Other recurrent mutations were
BRCA2 c.9098-9099insA (2 %), BRCA1 c.181T > G (1 %) and BRCA2 c.5851_5854delAGTT (1 %). Notably, BRCA1
c.5263_5264insC represented 56 % of all mutations identified in this series. Of the 22 patients with BRCA1
c.5263_5264insC, 9 were diagnosed with early onset breast cancer, 11 with TNBCs, 4 with bilateral breast cancer,
and 6 with both breast and ovarian cancer.
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Conclusions: This is the first comprehensive study of the BRCA1/2 mutation spectrum in Bulgaria and will assist
the establishment of efficient protocols for genetic testing and individualized risk assessment for Bulgarian
breast/ovarian cancer patients and healthy individuals at a high-risk.
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Breast cancer (BC) is the second most common cancer in
the world and, by far, the most frequent malignant disease
among women with an estimated 1.67 million new cases
diagnosed in 2012 (25 % of all cancer cases) [1]. Despite
the advancement of diagnostic techniques and treatment
in the last decade, BC is still the most frequent cause of
cancer death in women in less developed regions (324.000
deaths, 14.3 % of total) and the second cause of cancer
death in more developed regions (198.000 deaths, 15.4 %)
after lung cancer [1].
The etiology of BC is multifactorial and includes both
environmental and genetic factors, as well as genetic and
epigenetic changes during progression. Up to 5–10 % of
all BC cases and 10–15 % of all ovarian cancer (OC) cases
are due to germline mutations in one of the two breast
cancer susceptibility genes, BRCA1 [MIM#113705] and
BRCA2 [MIM#600185] [2–4].
Germline mutations in BRCA1 or BRCA2 explain about
50 % of disease aggregation in severely affected BC and
OC families while their prevalence is lower among BC and
OC patients unselected for family history or age of diagno-
sis: BRCA1 mutations are found in <1–7 % cases and
BRCA2 mutations in 1-3 % cases [5]. However, as high a
proportion as 84 % has been proposed for certain families
[6]. Higher prevalence is associated with a family history
of BC and/or OC, early onset, male BC or multiple tu-
mours such as bilateral breast cancer (BBC) or BC and
OC in the same patient [5]. Furthermore, some histopath-
ologic features such as lack of expression of estrogen, pro-
gesterone, and HER2 that define the biologically
aggressive and difficult to treat Triple Negative Breast
Cancers (TNBC) subtype, have been also attributed to
deleterious changes mainly in BRCA1 [7].
Pathogenic mutations in the BRCA1 and BRCA2 genes
confer high risks of breast, ovarian, and contralateral BC.
In a recent study the average cumulative risks by age
70 years for BRCA1 carriers were estimated to be 60 %
(95 % confidence interval [CI] = 44 to 75 %) for BC, 59 %
(95 % CI = 43 to 76 %) for OC, and 83 % (95 % CI = 69 to
94 %) for contralateral BC [8]. For BRCA2 carriers, the
corresponding risks were 55 % (95 % CI = 41 to 70 %) for
BC, 16.5 % (95 % CI = 7.5 to 34 %) for OC, and 62 %
(95 % CI = 44 % to 79.5 %) for contralateral BC [8].The prevalence of BRCA1 and BRCA2 mutations var-
ies between ethnic groups and geographical areas [9]. At
present, more than 1600 mutations in BRCA1 and more
than 1900 mutations in BRCA2 have been described
[10]. The spectrum of disease-associated BRCA1 and
BRCA2 alleles includes frameshift, nonsense, and mis-
sense mutations altering protein function, splice muta-
tions leading to truncation, as well as large genomic
rearrangements [11, 12]. The majority of germline muta-
tions identified in BRCA1 and BRCA2 are “private” or
family-specific [12]. However, several examples of
founder mutations have been described in certain geo-
graphical areas and ethnic communities where the
BRCA1 and BRCA2 mutational spectra are limited to a
few founders [13]. In fact, founder mutations have been
described in Ashkenazi Jews (AJ), Icelandic and Finnish
populations, in certain Dutch and French-Canadian
communities, and in countries like Turkey, Pakistan,
India, etc. [12–14].
Identification of BRCA1/2 mutation carriers allows
nondirective clinical decisions to be made in the man-
agement of high life time risk of BC/OC including
follow-up, prophylactic mastectomy and salpingooo-
phorectomy [7]. Furthermore, mutations in BRCA1/2
have been shown to be predictive of good response to
certain treatments, such as cisplatin and Poly (ADP)-Ri-
bose Polymerase (PARP) inhibitors [7].
According to the National Cancer Registry, BC is the
most common female malignancy in Bulgaria [15].
Around 3885 women are diagnosed with BC and 1285
die from the disease each year [15]. The first study of 20
Bulgarian familial BC patients was performed in 1998
aiming to develop a screening approach for the BRCA1
gene [16]. No mutations but only benign polymorphisms
were identified, most likely due to the small sample size,
the low stringency of the selection criteria and the lack
of complete analysis of BRCA2. Up to date no other sur-
veys on BRCA1/2 mutations in Bulgarian patients with
familial BC/OC have been published.
The lack of sufficient genetic studies for inherited mu-
tations in BRCA1/2 genes in the Bulgarian population
impedes the introduction of an effective mutation
screening that would identify the individuals at high risk
in BC/OC families. The aim of the present work was to
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tions in a cohort of 200 Bulgarian women with BC, ful-
filling the recognized international criteria [17, 18].
Direct sequencing of all coding exons and intron-exon
junctions of both genes was performed. This is the first
comprehensive study in Bulgaria aiming to ascertain the
contribution of BRCA1/2 germline mutations to familial
BC in the Bulgarian population.
Methods
Participants
In the present study 200 unrelated female patients with
primary BC, were selected from the Departments of
Surgery and General and Clinical Pathology, University
Hospital, “Alexandrovska”, Medical University of Sofia,
and the Clinic of Medical Oncology, Specialized Hospital
for Active Treatment in Oncology, Sofia, during their
treatment and follow up procedures for the period of
2007–2012. All patients were of Bulgarian ethnicity, ex-
cept one of Jewish origin. In personal interviews all clin-
ical information, histopathology reports and family history
were obtained from the patients. Their clinical features are
summarized in Table 1. Sixty-one firstdegree relatives (8
diagnosed with BC/OC and 53 healthy) of 30 probands
possessing a strong family history of BC/OC have been
also recruited. They were considered for testing of possibly
inherited damaging mutations. The cancer diagnosis of
the affected relatives was verified by their personal clinical
records.
Probands were selected for BRCA1/2 genetic testing
according to their age of diagnosis, family history and
tumour characteristics following the recognized Breast
Cancer Linkage Consortium (BCLC) and National Com-
prehensive Cancer Network (NCCN) Criteria, summa-
rized in Additional file 1: Table S1 [17, 18].
The distribution by criteria was as follows: 61 % (n =
122) fulfilled the BCLC criteria, 25 % (n = 50) - the NCCN
criteria and 14 % (n = 28) were TNBC. The predominant
was the group with early onset (38 %, n = 76), followed by
the group with family history of BC (37 %, n = 73) in at
least one first or second-degree relative diagnosed under
the age of 60 (Table 1). Fifteen % (n = 30) of the patients
were diagnosed with BBC, 6 % (n = 12) had a personal his-
tory of OC, whereas 5 % (n = 11) – family history of OC in
at least one first or second-degree relative diagnosed at
any age (Table 1). In addition to the TNBC group (14 %,
n = 28) (Table 1), 14 % (24/172) of the patients selected by
the BCLC and 2 NCCN criteria were also TNBC.
All deleterious mutations and some of the variants with
unknown clinical significance (VUSs) found in the patients
were validated in a control group of 96 healthy women
matched by age and ethnicity to the patients, without fam-
ily history of BC/OC. Only VUSs associated with BC in
previous studies were screened in the control group.The control group was collected through the clinical
specialists participating in the study and included
women undergoing regular prophylactic breast exami-
nations in the University Hospital “Alexandrovska”,
Medical University of Sofia, and Specialized Hospital for
Active Treatment in Oncology, Sofia. They were defined
as healthy based on the results of their last breast exami-
nations signed by breast specialists and in addition were
screened for lack of family history of BC/OC.
The study was approved by the Ethics Committee,
Medical University of Sofia. All persons confirmed their
agreement for participation upon signing an informed
consent and donated 10 ml of blood for genetic analysis.
The participants have also given consent for publishing
their genetic results and relevant clinical data anonym-
ously under a specific ID code assigned.
Genetic analysis
Total genomic DNA was isolated from peripheral blood
using a Chemagic Magnetic Separation Module and the
Chemagic DNA Blood kits according to the manufac-
turer’s recommendations (Chemagen, Perkin Elmer).
In order to amplify all coding sequences and exon-
intron junctions of the BRCA1/2 genes, we have used a
set of 81 primer pairs (33 for BRCA1 and 48 for BRCA2)
selected from the BIC database [10] or designed by
ExonPrimer software [19] (Additional file 2: Table S2).
PCR reactions were performed in 1X PCR buffer (Invitro-
gen), 0.4 mM of each dNTP, 1.5 mM MgCl2, 0.4 pmol of
each primer and 1U of Taq DNA polymerase (Invitrogen)
with 50 ng of genomic DNA in a final volume of 10 μl.
Amplification conditions were identical for all amplicons
of both genes, ranging in size from 190 to 720 bp, exclud-
ing the specific hybridization temperatures of the primer
pairs given in Additional file 2: Table S2 initial denatur-
ation at 94 °C (5 min); followed by 35 cycles of 94 °C
(45 s), 51 °C - 63 °C (35 s), 72 °C (30 s) and 72 °C
(10 min).
The mutation screening of BRCA1/2 genes was per-
formed using Sanger sequencing. PCR products were
purified with ExoSapIT (Affymetrix) according to the
manufacturer’s instructions – equal amounts of ExoSap
and dH2O (0.4 μl each) were added to 1 μl of PCR prod-
uct and incubated in a cycler for 30 min at 37 °C,
followed by 15 min at 80 °C. Sequencing reactions were
carried out with Big Dye® Terminator kit v3.1 (Life
Technologies) in a final volume of 10 μl under the fol-
lowing conditions: 96 °C (5 min), 96 °C (20 s), 55 °C
(20 s), 60 °C (2 min), 60 °C (5 min).
The fragments were analysed by automated Genetic
Analyser ABI 3130xl (Applied Biosystems). Obtained se-
quences were examined for the presence of mutations
by alignment with reference DNA sequence (GenBank
U14680 for BRCA1; GenBank U43746 for BRCA2) using
Table 1 Clinical features of 200 Bulgarian patients with primary
breast cancer selelected for age of diagnosis, family history and
tumour characteristics
N Proportion of patients
per feature (%)







Personal history of ovarian cancer
Yes 12 6
No 188 94
Family history of breast and ovarian cancer
Cancer in 1st or 2nd relative
Breast cancer dx < 60 73 36.5
Ovarian cancer, any age 11 5.5




























Table 1 Clinical features of 200 Bulgarian patients with primary





All patients 200 100 %
Dodova et al. BMC Cancer  (2015) 15:523 Page 4 of 16BLAST [20] and SeqScape TM v 2.0 (Applied Biosys-
tems, USA) software packages. Any mutation found was
confirmed in a second PCR reaction followed by sequen-
cing in both forward and reverse directions.
In silico analysis of sequence variants
Potential structural and functional effect of the mis-
sense VUSs was predicted by the following online tools:
PolyPhen 2 (http://genetics.bwh.harvard.edu/pph/), SIFT
(http://sift.jcvi.org/) and PROVEAN (http://provean.jc-
vi.org/index.php) [21–23].
Results
In the current study 200 Bulgarian patients selected by the
established genetic testing criteria were screened for muta-
tions in the BRCA1/2 genes by direct sequencing. The
mean age of the patients at diagnosis was 49.5 (25–74)
years. Thirty eight percent (n = 76) of the patients were
under 40, 49.5 % (n = 99) between 41 and 60, and 12.5 %
(n = 25) between 61 and 80 years of age (Table 1).
Upon direct sequencing, 13 different damaging muta-
tions were identified, 6 in BRCA1 (four frameshift, one
nonsense, one missense) and 7 frameshift in BRCA2
(Table 2). Of those 84.61 % (11/13) were frameshift mu-
tations seen in 18 % (36/200) of the patients. None of
the pathogenic mutations was found in the healthy
controls.
BRCA1 mutations
In the BRCA1 gene we have identified six unequivocally
deleterious mutations of which four frameshift, one non-
sense and one missense (Table 2). Among the frameshift
mutations two: c.5030_5033delCTAA and c.5263_5264insC
with frequencies of 0.5 % and 11 %, respectively, had been
previously reported and two, namely c.464delA and
c.5397_5403delCCCTTGG with frequencies of 0.5 % each
were novel (Table 2). The mutation c.464delA, located
in exon 8, was detected in a patient BC134 diagnosed
with TNBC at the age of 54 with three cases of BC in
her pedigree (Table 3). The second novel mutation
c.5397_5403delCCCTTGG in exon 22 was also found in
an individual with TNBC (BC205) diagnosed at the age
of 51 with family history of BC and PC (Table 3).
Table 2 BRCA1/2 damaging mutations in Bulgarian BC patients
Exon HGVS nomenclature BIC nomenclature Protein nomenclature Functional domain Mutation type Times observed
BRCA1
5 c.181 T > G C61G p.Cys61Gly Ring finger Missense 2
8 c.464delA 583delA p.Gln155fs - Frameshift 1
15 c.4603G > T E1535X p.Glu1535Ter AD1 Nonsense 1
17 c.5030_5033delCTAA 5149del4 p.Thr1677_Asn1678delinsIlefs BRCT1/AD2 Frameshift 1
20 c.5263_5264insC 5382insC p.Ser1755delinsSerProfs linker Frameshift 22
22 c.5397_5403delCCCTTGG 5515del7 p.Thr1799delins BRCT2/AD2 Frameshift 1
BRCA2
11 c.5718_5719delCT 5946delCT p.Asn1906_Ser1907 = fs - Frameshift 1
11 c.5851_5854delAGTT 6079del4 p.Ser1951_Leu1952delinsTrpfs - Frameshift 2
11 c.5946delT 6174delT p.Ser1982Argfs BRC repeat7 Frameshift 1
17 c.7910_7914delCCTTT 8138del5 p.Ala2637_Phe2638delinsAlafs Helical Domain Frameshift 1
20 c.8532_8533delAA 8760delAA p.Glu2844fs Tower Frameshift 1
23 c.9098_9099insA 9326insA p.Thr3033delinsThrSerfs OB2 Frameshift 4
27 c.9682delA 9908delA p.Gln3227fs - Frameshift 1
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was observed in one patient (BC194) without family his-
tory diagnosed with TNBC at the age of 63 (Table 3).
Twenty-two of the patients (11 %) harboured the muta-
tion c.5263_5264insC in BRCA1 exon 20 (Table 3). Of
those six (BC6, BC21, BC99, BC143, BC152 and BC171)
had developed both BC and OC, four were diagnosed
with BBC (BC7, BC39, BC152 and BC204). Eleven of the
cases were TNBC (BC73, BC111, BC121, BC142, BC143,
BC155, BC161, BC164, BC171, BC175 and BC190) of
which 5 (BC111, BC121, BC142, BC155 and BC190) de-
veloped the disease before the age of 40. Altogether in 9
of the patients, the c.5263_5264insC mutation correlated
with early onset (BC3, BC39, BC140, BC111, BC121,
BC142, BC155, BC190 and BC204).
In addition to the listed above indels we found two
deleterious point mutations that had previously been re-
ported (Table 2): one nonsense (c.4603G > T) with a fre-
quency of 0.5 % and one missense (c.181T > G) with a
frequency of 1 %. The mutation c.4603G > T was carried
by a patient BC37 with early onset (Table 3) while
c.181T > G was detected in two patients (BC28 and
BC132), with early onset and BBC, respectively
(Table 3).
BRCA2 mutations
Seven damaging frameshift mutations were found in
BRCA2 (Table 2), of which five had previously been re-
ported: c.5851_5854delAGTT, c.5946delT, c.5718_5
719delCT, c.7910_7914delCCTTT, c.9098_9099insA;
and two novel: c.8532_8533delAA and c.9682delA.
The most frequent BRCA2 frameshift mutation
c.9098_9099insA, located in exon 23, was observed infour patients (BC32, BC81, BC85 and BC88) with famil-
ial BC (2 %). In addition one of them (BC88) had TNBC
(Table 4).
The second in frequency BRCA2 frameshift mutation
c.5851_5854delAGTT, located in exon 11, was found in
two patients (1 %): BC76 with a family history of BC and
stomach cancer, diagnosed with TNBC at the age of 53,
and BC58 with family history of BC and CRC, diagnosed
with BC at the age of 48 (Table 4).
The rest of the BRCA2 frameshift mutations were seen
only once in our study with a frequency of 0.5 % each
(Table 2). Two deletions in exon 11: c.5718_5719delCT
and c.5946delT were observed respectively in a patient
BC90 with early onset (35 years) and in a Jewish patient
BC52 with family history of BC, diagnosed with both
BBC (at the age of 41/68) and OC (at the age of 59)
(Table 4).
The deletion c.7910_7914delCCTTT, located in exon
17, was present in a patient BC19 with early onset, BBC
(at the age of 37/41) and family history of BC/OC
(Table 4).
One of the novel BRCA2 deletions c.8532_8533delAA,
located in exon 20, was found in a patient BC87 with
BBC and early onset (at the age of 30/37). Interestingly,
the second new BRCA2 deletion c.9682delA, located in
exon 27, was also observed in a patient (BC228) with
BBC (Table 4).
Unclassified variants
Additional 50 sequence variants were identified at
BRCA1 and BRCA2, with either benign or unknown
pathogenic effect. All of them were named sequence var-
iants due to inconsistency in their classification in the
Table 3 Clinical data of the carriers of damaging BRCA1 mutation
BC№ HGVS nomenclature Diagnosis and age of onset ER PR HER2 TNM Grade Stage Other cancer in patient
(age of onset)
Family history of cancer and age of diagnosis
3 c.5263_5264insC BC (36) NA NA NA NA NA NA DC (41) Grandmother - BC (NA)
6 c.5263_5264insC IDC (43) - 1+ NA pT2N0Mx NA II OC (45) Mother – BC (50), sister - BBC (42/53),
grandmother – BC and OC (50)
7 c.5263_5264insC BBC (42) 3+/− 3+/− 1+/1+ pT1N0M0/pT1bpN1M0 G2/G2 I/IIB Grandmother - BC (76), aunt BC(81), father seminoma
(NA), cousin with cancer of the oral cavity (NA)
17 c.5263_5264insC IDC (34) 2+ 2+ NA NA G2 NA No
21 c.5263_5264insC IDC (48) NA NA NA NA NA NA OC (48) Grandfather - GC (70), grandfather – BT (NA),
PC (NA), aunt - CGO (50), cousin - BC (54)
28 c.181 T > G BBC (52/60) NA NA NA NA NA NA OC (52) Brother with bone cancer (47)
37 c.4603G > T IDC (37) - - - pT1cN1M0 G2 II FtC (41) Grandfather - PC (76), grandfather - LC (69),
grandmother - CRC (60)
39 c.5263_5264insC BBC(37/55) NA/- NA/- NA/- NA NA NA Uncle - PrC (66)
73 c.5263_5264insC IDLC (53) - - - pT2pN0M0 G3 II Mother - BC (47) and CRC (71)
79 c.5263_5264insC IDC (42) NA NA 1+ NA NA NA Grandmother - GC(70), mother – BBC (27/30),
uncle – leukemia (67), grandmother - CLv (75)
99 c.5263_5264insC IDC (40) NA NA NA pT1N0M0 G2 NA OC (46) Grandmother – unknown cancer (>80),
mother-CrC (NA), mother’s sister – Paget’s
disease of the nipple (NA)
111 c.5263_5264insC ACC (36) - - - NA G1 NA No
121 c.5263_5264insC IDC (34) - - - pT1N0M0 G3 I Father – pelvic cancer (NA), cousin - BC (30)
132 c.181 T > G IDC (39) - - - pT1pN0M0 G2 I Grandmother - BC (60), mother -BBC (32/40)
134 c.464delA IDC (54) - - - pT1N1M0 G3 II Aunt - BC (47), grandmother and grandmother’s
sister - BC(NA), father - LC (NA)
140 c.5263_5264insC IDC (32) 1+ 2+ 2+ pT2pN0M0 G2 IIa Mother - BBC (31/37), grandmother - EC, CRC
(50/53), grandfather - LC (59), grandmother - BC (NA)
142 c.5263_5264insC IDC (31) - - - pT1pN0M0 G2-3 I No
143 c.5263_5264insC IDC (51) - - - pT2N0M0 G3 I OC (51) Uncle - PC (68), grandmother LC (44), cousin - OC (37)
152 c.5263_5264insC BBC (41) NA NA NA NA NA NA OC (58) Mother - BBC (NA)
155 c.5263_5264insC BC (29) - - - NA NA NA Grandmother - BC, ThC (50/70), cousin - BC (50),
cousin - OC (48)
161 c.5263_5264insC IDC (43) - - - NA NA NA Mother – OC (62)
164 c.5263_5264insC IDC (45) - - - NA NA NA Mother - BC (NA)
171 c.5263_5264insC BC (53) - - - NA NA NA OC (NA) Grandmother - BC (43), mother - BC (53) and OC (63)
175 c.5263_5264insC MBC (33) - - - pT1сN2M0 G2 II No













Table 3 Clinical data of the carriers of damaging BRCA1 mutation (Continued)
190 c.5263_5264insC IDC (33) - - - pT1bpN0M0 G2 I Grandmother - BC (47), mother - OC (52),
grandfather - CRC (62)
204 c.5263_5264insC BBC (35/48) NA NA NA NA NA NA Mother with bladder cancer in doubt
205 c.5397_5403 IDC (51) - - - pT1pN1M0 G3 II Grandmother - BC (30), father – PC (NA)
delCCCTTGG
BC№ - case identifier, BC – breast cancer, BBC – bilateral breast cancer, IDC – invasive ductal carcinoma, ILC - invasive lobular carcinoma, IDLC - infiltrating ductal/ lobular cancer, MBC - medullary breast cancer,
ACC – adenoid cystic carcinoma, ThC – throat cancer, LyC – laryngeal cancer, PC – prostate cancer, LC – lung cancer, CRC – colorectal carcinoma, PrC – pancreatic cancer, CLv – cancer of the liver, GC - gastric cancer,












Table 4 Clinical data of the carriers of damaging BRCA2 mutation carriers
BC№ HGVSnomenclature Diagnosis and age of onset ER PR HER2 TNM Grade Stage Other cancer in patient Family history of cancer and age of diagnosis
19 c.7910_7914 BBC (31/37) NA/ NA NA/ NA NA/ NA NA/ NA NA/ NA NA Cousin - BBC (41/49), father - GC (NA), aunt - OC (NA)
delCCTTT
24 c.9682delA BBC (52) NA NA NA NA NA NA NA
32 c.9098_9099insA IDC (50) - - 3+ NA G3 NA Aunt – BC (NA)
52 c.5946delT BBC (41/68) NA/ NA/ NA/ NA NA/ NA NA/ NA NA OC (59) Mother - BC (36) sister - BC (46) and CRC (65),
father - LC, ethnicity - Jewish
3+ 3+
58 c.5851_5854 IDC (48) 3+ 3+ 2+ pT1N0Mx G3 NA Mother – BC (NA), brother and sister of the
mother – CRC (NA), her father – LC (NA),
cousin – CRC (NA), a brother of the
father – CLv (NA) and his children - BC
(35) and - LC (50)
delAGTT
76 c.5851_5854 IDLC (53) - - - pT1pN0M0 G2 NA Cousin - BC (65), father - StC (54)
delAGTT
81 c.9098_9099insA BC (59) NA NA NA NA NA NA Sister - BC (52), aunt - BC (67)
85 c.9098_9099insA IDC (52) 3+ - - pT1pN2pMx G3 III Aunt - BC (42), grandfather - head and
neck cancer (NA)
87 c.8532_8533 BBC (30/37) 3+/ - NA pT1bpN0M0/ G2/ I/I Mother BBC (NA)
delAA 3+ /3+ /1+ pT1bpN0M0 NA
88 c.9098_9099insA IDLC (61) - - - pT2pN0M0 G2-3 Iia Grandfather - ThC (48), mother - BC (60),
two cousins - BC (34/47)
90 c.5718_5719 IDC (35) 2+ 3+ 3+ pT2pN2M0 G2 III Grandfather - LyC (NA), grandmother - unclear
malignant disease, most likely melanoma (NA)
delCT
BC№ - case identifier, BC – breast cancer, BBC – bilateral breast cancer, IDC – invasive ductal carcinoma, ILC - invasive lobular carcinoma, IDLC - infiltrating ductal/ lobular cancer, MBC - medullary breast cancer,
ACC – adenoid cystic carcinoma, ThC – throat cancer, LyC – laryngeal cancer, PC – prostate cancer, LC – lung cancer, CRC – colorectal carcinoma, PrC – pancreatic cancer, CLv – cancer of the liver, GC - gastric cancer,












Table 5 Unclassified BRCA1/2 variants in Bulgarian BC patients




















5 c.139 T > G C47G p.Cys47Gly ring finger missense 0.002 200 0.000 96 NA
8 c.536A > G Y179C p.Tyr179Cys - missense 0.002 194 0.000 96 0.001
11 c.736 T > G L246V p.Leu246Val - missense 0.002 200 - - 0.002
11 c. 1067A > G Q356R p. Gln356Arg - missense 0.072 194 0.052 96 0.049
11 c.1456 T > C F486L p.Phe486Leu - missense 0.002 200 - - 0.001
11 c.1648A > C N550H p.Asn550His - missense 0.002 200 0.00 96 0.001
11 c.2077G > A D693H p.Asp693Asn - missense 0.065 192 0.083 96 0.097
11 c.2612C > T P871L p.Pro871Leu - missense 0.350 193 0.391 96 0.336
11 c.3113A > G E1038G p.Glu1038Gly - missense 0.335 195 0.349 96 0.358
11 c.3119G > A S1040N p.Ser1040Asn - missense 0.023 195 0.026 96 0.580
11 c.3548A > G K1183R p.Lys1183Arg - missense 0.339 193 0.302 96 0.332
11 c.3999 T > C V1333A p. Val1333Ala AD1 missense 0.002 200 0.00 96 -
16 c.4837A > G S1613C p.Ser1613Gly AD2 missense 0.323 193 0.318 96 0.314
16 c.4956G > A M1652I p.Met1652Ile BRCT1/AD2 missense 0.036 193 0.016 96 0.005
9 c.591C > T C197C p.Cys197= - cds-synon 0.007 193 0.00 96 0.001
11 c.2082C > T S694S p.Ser694= - cds-synon 0.323 192 0.318 96 0.280
11 c.2311 T > C L771L p.Leu771= - cds-synon 0.233 191 - - 0.332
13 c.4308 T > C S1436S p.Ser1436= AD1 cds-synon 0.337 194 - - 0.332
7 c.441 + 36_441
+ 38delCTT
IVS7 + 36delCTT - - IVS 0.194 195 0.354 96 NA
8 c.442-34C > T IVS7-34 C > T - - IVS 0.230 194 0.224 96 0.257
9 c.548-58delT IVS8-58delT - - IVS 0.196 193 0.385 96 0.331
15 c.4485-63C > G IVS14-63C > G - - IVS 0.330 197 - - 0.321
18 c.5075-53C > T IVS17-53 C > T - - IVS 0.010 194 - - 0.034
20 c.5277 + 56delGTA IVS20 + 56insGTA - - IVS 0.002 200 0.00 96 -
BRCA2
10 c.865A > C N289H p.Asn289His - missense 0.050 185 - - 0.031
10 c.978C > A S326R p.Ser326Arg - missense 0.010 185 - - 0.001
10 c.1114A > C H372N p.Asn372His - missense 0.283 185 - - 0.300
11 c.2971A > G N991D p.Asn991Asp - missense 0.050 185 - - 0.031
11 c.3515C > T S1172L p.Ser1172Leu - missense 0.002 185 0.00 96 0.001
11 c.5744C > T T1915M p.Thr1915Met - missense 0.017 200 0.016 96 0.032
11 c.6100C > T R2034C p.Arg2034Cys - missense 0.002 200 - - 0.018
11 c.6322C > T R2108C p.Arg2108Cys - missense 0.002 200 - - 0.001
15 c.7469 T > C I2490T p.Ile2490Thr Helical
Domain
missense 0.002 185 - - 0.000
23 c.9104A > C Y3035S p.Tyr3035Cys OB2 missense 0.005 200 0.005 96 NA
11 c.4146_4148delAGA E1382del delinsAsp - Cds_indel 0.002 200 - - NA
10 c.1365A > G S455S p.Ser455= - Cds-synon 0.030 185 - - 0.031
11 c.2229 T > C H743H p.His743= - Cds-synon 0.035 184 - - 0.031
11 c.3396A > C K1132K p.Lys1132= - Cds-synon 0.285 182 - - 0.250
11 c.3807 T > C V1269V p.Val1269= - Cds-synon 0.189 185 - - 0.226
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14 c.7242A > G S2414S p.Ser2414= - Cds-synon 0.184 184 - - 0.190
2 c.-26G > A 203G > A - - UTR-5 0.247 190 - - 0.199
27 c.*105A > C IVS27 + 104A > C - - UTR-3 0.183 185 - - 0.274
4 c.425 + 67A > C IVS4 + 67A > C - - IVS 0.050 184 - - 0.031
4 c.425 + 147G > T IVS4 + 147G > T - - IVS 0.040 184 - - 0.062
5_6 c.426-89 T > C IVS4-89 T > C - - IVS 0.040 184 - - 0.031
8 c.681 + 56C > T IVS8 + 56C > T - - IVS 0.060 185 - - 0.133
11 c.6841 + 80_6841 + 83 IVS11 + 80 - - IVS 0.289 185 - - 0.294
delTTAA delTTAA




- - IVS 0.032 186 - - 0.043
15 c.7617 + 28C > A IVS15 + 28 C > A - - IVS 0.002 200 - - -
17 c.7806-14 T > C IVS16-14 T > C - - IVS 0.320 187 0.469 96 0.465
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cluded missense, synonymous and intronic variants, as
well as one inframe deletion (Table 5).
In total 24 missense VUSs were identified, of which 14
in BRCA1and 10 in the BRCA2 (Table 5). According to
their minor allele frequencies (MAFs) in the patients
they can be divided into two groups: rare variants with
MAFs between 0.0025 and 0.005, and frequent variants
with MAFs > 0.005. We have compared the MAFs of the
unclassified missense variants found among patients
with other Europeans [24] and with healthy controls
(only for the variants associated with BC in previous stud-
ies). The studied variants in the control group included
VUSs in exons 5 (c.139 T >G); 7 (c.441 + 36_441 +
38delCTT); 8 (c.536A >G, c.442-34C > T); 9 (c.591C > T,
c.548-58delT); 11 (c.1067A >G, c.1648A > C, c.2077G > A,
c.2612C > T, c.3113A >G, c.3119G > A, c.3548A >G,
c.3999 T > C, c.2082C > T); 16 (c.4837A >G, c.4956G >A);
and 20 (c.5277 + 56delGTA) of BRCA1 and the variants in
exons 11 (c.3515C > T, c.5744C > T); 17 (c.7806-14 T > C);
and 23 (c.9104A > C) of BRCA2 (Table 5). Variants for
which no information for association with BC was found
in the databases were not screened in the healthy controls
but were included in Table 5. In addition in silico analysis
was conducted in order to predict potential deleterious ef-
fect of all detected missense VUSs (Table 6).
Six rare BRCA1 missense variants were seen in pa-
tients (Table 5): c.139 T > G, c.536A > G, c.736 T > G,
c.1456 T > C, c.1648A > C and c.3999 T > C. Of those
c.3999 T > C, causing a replacement of alanine to valine
at codon1333 has never been reported. Even though
c.3999 T > C was observed in a patient BC20 with BBC
and early onset in the absence of other pathogenic muta-
tions, the in silico analysis did not confirm its pathogenic
effect (Table 6).The missense variants c.139T > G had been predicted
to be deleterious in previous functional studies [25].
Inour study it was found in one patient (0.5 %) with
TNBC BC10 and appeared to be clinically important ac-
cording to wo prediction programs (POLYPHEN 2 and
SIFT), while PROVEAN predicted it as neutral (Table 6).
One patient with family history of BC117 was the only
carrier of three rare missense variants c.536A > G,
c.1456T > C and c.1648A > C, which were not seen in
the control group (Table 5). Another rare missense
BRCA1 variant c.736T > G, listed as variant of unknown
significance (VUS) in BIC [10] and neutral in UMD
(Universal Mutation Database) [26], was found in patient
BC30 with BBC (Table 5).
Eight missense variants were observed in BRCA1 with
MAF>0.005 in both patients and controls (Table 5).
They were designated as VUS in BIC and neutral in
UMD databases (Table 5). Only two of them (c.1067A >
G and c.3113A > G) appeared to be deleterious accord-
ing to the conducted in silico analysis (Table 6).
Four synonymous and 6 intronic variants were also de-
tected in the BRCA1 gene (Table 2). Of those c.5277 +
62_c.5277 + 64delGTA had not previously been reported
and was seen in two patients (1 %) but not in the control
group (Table 5). The variant c.591C > T was more fre-
quent in patients (MAF = 0.007), but was not found in
the control group and was rare in other Europeans
(MAF = 0.001) (Table 5). All other variants had MAF >
0.005 in both patients and other Europeans, except
c.441 + 36_441 + 38delCTT, for which data about MAF
were not available in the databases (Table 2). Variants
c.2082C > T, c.441 + 36_441 + 38delCTT, c.442-34C > T
and c.548-58delT were also genotyped and found with
high frequencies (MAF > 0.005) in the healthy controls
(Table 5).
Table 6 Assessment of the clinical effect of unclassified BRCA1/2 missense variants detected in Bulgarian BC patients
Exon HGVS nomenclature BIC nomenclature BIC UMD POLYPHEN2 SIFT PROVEAN
BRCA1
5 c.139 T > G C47G unknown - probably damaging damaging neutral
8 c.536A > G Y179C unknown neutral damaging tolerated neutral
11 c.736 T > G L246V unknown neutral probably damaging tolerated neutral
11 c. 1067A > G Q356R unknown neutral probably damaging damaging deleterious
11 c.1456 T > C F486L unknown neutral benign tolerated neutral
11 c.1648A > C N550H unknown neutral probably damaging damaging deleterious
11 c.2077G > A D693H no neutral benign tolerated deleterious
11 c.2612C > T P871L no neutral benign tolerated neutral
11 c.3113A > G E1038G no neutral possibly damaging damaging neutral
11 c.3119G > A S1040N unknown neutral probably damaging damaging neutral
11 c.3548A > G K1183R no neutral benign tolerated neutral
11 c. 3999 T > C V1333A - - possibly damaging tolerated neutral
16 c.4837A > G S1613C no neutral benign damaging neutral
16 c.4956G > A M1652I unknown neutral benign tolerated neutral
BRCA2
10 c.865A > C N289H no neutral benign tolerated neutral
10 c.978C > A S326R no neutral benign tolerated neutral
10 c.1114A > C H372N no neutral benign tolerated neutral
11 c.2971A > G N991D no polymorphism benign tolerated neutral
11 c.3515C > T S1172L unknown likely neutral probably damaging damaging deleterious
11 c.5744C > T T1915M no neutral benign tolerated neutral
11 c.6100C > T R2034C unknown neutral probably damaging tolerated deleterious
11 c.6322C > T R2108C unknown UV benign tolerated neutral
15 c.7469 T > C I2490T no UV benign tolerated neutral
23 c.9104A > C Y3035S unknown UV benign damaging Neutral
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fied in BRCA2 (Table 5). Three of them c.6322C > T,
c.7469 T > C andc.9104A > C were classified as VUS in
both BIC [10] and UMD [26] databases, while c.3515C > T
and c.6101G > A were designated as VUS only in BIC
(Table 5). In UMD c.3515C > T was suggested to be likely
neutral but no information was available for c.6101G >A
(Table 5). The in silico analysis predicted pathogenic effect
of both c.3515C > T and c.6101G >A (Table 6).
We found four frequent (MAF > 0.005) missense vari-
ants in BRCA2 (Table 5). None of them was predicted to
be pathogenic upon in silico analysis (Table 6). In
addition we detected one in frame deletion of glutamate
in exon 11- c.4146_4148delAGA (MAF = 0.0025), which
was classified as VUS in both BIC [10] and LOVD (Leiden
Open Variation Database) [27].
The other BRCA2 sequence variants were observed with
high frequencies in patients (MAF > 0.005), similar to
those found in other Europeans (Table 5). Among them
seven were synonymous replacements; two variants –c.-26G > A and c.*105A > C, were localized in 5′-UTR- and
3′-UTR, respectively and 8 were intronic. One of the in-
tronic variants c.7617 + 28C > A was novel (Table 5).
Discussion
This is the first comprehensive study aiming to ascertain
the contribution of BRCA1/2 germline mutations to BC de-
velopment in the Bulgarian population, where 1285 women
die from the disease each year [15]. The thorough mutation
screening of all coding sequences and exon-intron junc-
tions of BRCA1/2 genes in a cohort of 200 Bulgarian
women with primary invasive BC and with personal or
family history of BC/OC, selected according to the recog-
nised international criteria [17, 18] led to the identification
of pathogenic mutations in 19.5 % of them (39/200).
We have found 13 unequivocally deleterious muta-
tions of which 6 in BRCA1 and 7 in BRCA2 gene
(Table 2). The predominant mutations seen in 18 % of the
studied group of patients were frameshift mutations lead-
ing to truncated proteins with impaired function. In total
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BRCA2 The other two mutations identified were nonsense
and missense mutation in BRCA1, each accounting for
7.7 % (1/13) of all disease causing mutations.
The median age of diagnosis was 46 (range 29–63 years)
in the 28 BC with a BRCA1 mutation (Table 3) and 45.5
(range 30–61 years) in the 11 BC with a BRCA2 mutation
(Table 4), compared with a median age of diagnosis of
49.6 years (range 25–74 years) for the 161 cases without a
mutation. A BRCA1 mutation was found in 18.4 % (14 of
76) women diagnosed with BC at or under the age of 40
compared to 11.2 % (14 of 124) of women diagnosed at a
later age (Table 3); a BRCA2 mutation was found in 4 % (3
of 76) women diagnosed with BC at or under the age of 40
compared to 6.5 % (8 of 124) of women diagnosed at a
later age (Table 4). A mutation was present in 26.8 % (22
of 82) BC patients with a positive family history and in
14.4 % (17 of 118) of women with a negative family history.BRCA1 mutations
The most prevalent mutation observed in 22 patients
(11 %) was BRCA1 c.5263_5264insC, a known Slavic
mutation with founder effect in Eastern European as
well as AJ communities, (Table 2). This frameshift muta-
tion is the second most frequently reported in BIC data-
base [10]. It has been found with various frequencies in
high risk BC/OC families from Poland (34 %), Russia
(14 %), Hungary (14 %), Slovenia (13 %), AJ (10 %),
Greece (8 %), Germany (4 %), and Italy (3 %) [13]. The
c.5263_5264insC was not found in Spain and Portugal
and it has been observed with a low frequency in the
Netherlands, Belgium and Scandinavian countries [13].
In Russia, Belarus, Poland, Latvia, Czech Republic,
Greece and Lithuania it accounts for respectively 94 %,
73 %, 60 %, 55 %, 37–52 %, 46 % and 34 % of all BRCA1
mutations [13].
Being a founder mutation in Greece [28], c.5263_
5264insC has been detected in other Balkan countries such
as Romania, Turkey, Serbia, Croatia, and Macedonia but
without a founder effect [29–33]. Apparently Bulgaria is the
second Balkan country in which the most prevalent Slavic
mutation c.5263_5264insC has a founder effect accounting
for a very high proportion, about 76 % (22/29) from all de-
tected BRCA1 mutations (Table 3), with high intermediate
frequency (11 %) compared to the other Central and
Eastern European countries [13].
Originally c.5263_5264insC was described as a founder
mutation in AJ, but recent haplotype analysis suggested
that it most likely originated in Northern Russia or pos-
sibly Scandinavia, between 1800 and 1500 years ago, and
was subsequently spread to the various populations from
East to West and nearly worldwide [34]. A common an-
cestor for families with c.5263_5264insC mutation,reported from Europe, Brazil, North America and India
is evident [34–36].
We suppose that in Bulgaria the mutation c.5263_
5264insC also has a Slavic origin since the modern
Bulgarian nation originated as a mixture of Slavic, Thracian
and Bulgar tribes more than 1300 years ago. A detailed
haplotype analysis is necessary to prove this hypothesis.
The increased risk of BC and OC in c.5263_5264insC
mutation carriers has been estimated at 67 % (95 % CI,
36–83 %) and 33 % (95 % CI, 8–50 %), respectively [5].
At a molecular level it leads to a stop codon at position
1829 and respectively to a truncated protein that lacks
its C-terminal BRCT motif. In our study the presence of
the c.5263_5264insC mutation in the patients was asso-
ciated with early onset in 9 patients (BC3, BC39, BC140,
BC111, BC121, BC142, BC155, BC190 and BC204), BBC
in 4 patients (BC7, BC39, BC152 and BC204), two sub-
sequent events of BC and OC in 6 patients (BC6, BC21,
BC99, BC143, BC152 and BC171) and/or TNBC in 11
patients (BC73, BC111, BC121, BC142, BC143, BC155,
BC161, BC164, BC171, BC175 and BC190) (Table 3).
Several carriers were also identified among the relatives
of the patients with c.5263_5264insC (one individual
with OC, another with both BC and OC, as well as three
healthy individuals).
The mutation c.5030_5033delCTAA located in BRCA1
exon 17 is a prevalent frameshift mutation reported in at
least five French families with BC/OC and most likely
originating from a common ancestor (13). It has been
also detected in BC patients with early onset from USA
(0.35 %, 1/282) and Taiwan (2.8 %, 1/36) [37, 38]. We
observed the mutation in one patient (0.5 %, 1/200) with
TNBC (BC194) diagnosed at the age of 63 (Table 4).
According to BIC database [10] the majority of the
pathogenic mutations in BRCA1/2 are frameshift mutations
(around 70 %), while nonsense and missense mutations
contribute with around 10 % each. In the present study we
have identified only two previously reported BRCA1 point
mutations with clear pathogeniceffect:c.181T >G and
c.4603G >T, located in exon 5 and 15, respectively (Table 2).
The mutation c.4603G >T was reported several times in
BIC as clinically important and it was found in Non-AJ pa-
tients from America and Venezuela [10, 39]. Among the
studied Bulgarian patients c.4603G >T was observed only
once (0.5 %) and was associated with early onset BC (BC37,
Table 3).
Following the most prevalent mutation c.5263_5264insC,
the missense variant c.181T >G has been recognised as the
second most frequent mutation in Poland and other Euro-
pean countries among BC/OC families [13]. These two
founder mutations accounted for 70–90 % of the BRCA1
mutations found in the Polish population, 80 % in Hungary
and 28 % in Germany, respectively [13]. Located in the
RING domain of BRCA1, c.181T >G has been found to
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the protein in functional studies [25].
In Austria, Slovenia, and Czech Republic the families
with c.181T >G mutation represented 15 %, 18 % and 9 %,
respectively, of all families carrying BRCA1 mutations [13].
It has been also known as one of the three founder muta-
tions in Byelorussian population with frequencies of 1 % in
unselected BC families and 0.2 % in control individuals
[40]. The mutation was detected at a very low rate in our
neighboring countries such as Greece, Serbia and Romania,
as well as in Croatia, Austria, Slovakia, Ukraine, Latvia,
Lithuania and Russia [13]. In our studyc.181T >G was
found as a disease causing mutation in two patients (1 %),
with early onset (BC132) and BBC (BC28), respectively
(Table 3).
We have identified two new frameshift mutations in the
BRCA1 gene: c.464delA and c.5397_5403delCCCTTGG
with 0.5 % frequency each (Table 2). The mutation
c.464delA, located in exons 8, leads to a truncated protein,
lacking its Coiled Coil and BRCT domains and was de-
tected in a patient BC134 with TNBC diagnosed at the age
of 54 with three cases of BC in her pedigree (Table 3).
Three of her healthy first-degree relatives (sister, and 2
sons) were also carriers of the mutation (Additional file 3:
Figure S1). The second novel mutation c.5397_5403delC
CCTTGG in exon 22 residing in the BRCT motif leads to
a truncated protein without C-terminal BRCA2/AD2 do-
main. It was found in an individual BC205 with TNBC di-
agnosed at the age of 51 with family history of BC
(Table 3, Additional file 4: Figure S2).
BRCA2 mutations
The second in frequency (2 %) mutation observed in our
study was the insertion c.9098_9099insA, located in exon
23 of BRCA2 gene. It has been reported as one of the most
frequent BRCA1/2 mutations in Germany with a possible
founder effect [13]. Together with c.5946delT it also
accounted for 50 % of all BRCA2 mutations in BC/OC fam-
ilies from Hungary [13]. The consequence of this mutation
is a premature stop codon at position 3042 that leads to a
truncated protein losing its C terminal OB3 and NLC mo-
tifs and thus the ability to bind a DSS1 protein that regu-
lates its repairing function (Table 2). All four carriers of the
insertion c.9098_9099insA in our study (BC32, BC81, BC85
and BC88) had family history of BC, and were diagnosed
with BC between 50 and 61 years of age. One of them
(BC88) developed TNBC (Table 4).
Three of the observed known frameshift mutations were
located in exon 11 of BRCA2 (Table 2): c.5851_5854d
elAGTT, c.5946delT, and c.5718_5719delCT. The deletion
c.5851_5854delAGTT has been detected with a low fre-
quency in cohorts of Italian, American Asian and Indian
BC/OC patients [41, 42]. In the present investigation we
have identified two (1 %) unrelated Bulgarian patientsharbouring c.5851_5854delAGTT deletion. One of the pa-
tients (BC76) with a family history of BC and stomach can-
cer was diagnosed with TNBC at the age of 53, while the
other (BC58) developed BC at the age of 48 and had a fam-
ily history of BC and CRC (Table 4).
The c.5946delTwas found in one patient with Jewish ori-
gin and family history of BC (BC52), who had developed
both BBC at the age of 41/68 and OC at the age of 59
(Table 4). A healthy daughter of the patient also harboured
the mutation. The c.5946delT deletion has been recognised
as one of the three founder mutations in AJ, together with
the two BRCA1 indels c.68_69 delAG and c.5263_5264insC
[13]. The mutation c.5946delT has been also detected in
non-Jewish populations such as the Hungarian BC/ OC
families [13].
The third mutation, observed in exon 11 of BRCA2
c.5718_5719delCT, was reported several times in BIC data-
base [10]. It has been found with a very low frequency in
patients with BC, OC and PC from Germany, UK and
North America [10, 43]. The mutation was found with
similar low frequency (0.5 %) in our study and correlated
with early onset (BC90, Table 4).
Another recurrent mutation according to BIC database
[10], c.7910_7914delCCTTT, located in BRCA2exon 17,
was identified in a proband BC19 (0.5 %) with early onset
BBC (at the age of 37/41) with family history of BC/OC
(Table 4). A cousin of the patient also harboured the muta-
tion and possessed identical clinical phenotype. Interest-
ingly, c.7910_7914delCCTTT has been associated with
BBC in other European populations as well [40]. It was first
reported in UK and was further observed with low frequen-
cies in patients with BBC from Germany and Denmark and
with a frequency of 3.6 % (1/27) among males with sporadic
BC in the Polish population [44, 45].
Two novel frameshift mutations were found in BRCA2:
c.8532_8533delAA and c.9682delA with frequency of
0.5 % each (Table 2). The mutation c.8532_8533delAA, lo-
cated in exon 20, was found in a patient BC87 with BBC
(at the age of 30 and 37) and early onset (Table 4). The pa-
tient’s mother was also diagnosed with BBC and carried
the mutation (Additional file 5: Figure S3). This mutation
is located in the Tower domain of the protein and termi-
nates the translation at the middle of OB2 domain as a re-
sult of which BRCA2 lacks its OB3 and NLC motifs at the
C terminus. Similarly the second novel BRCA2 deletion
located in exon 27 was observed in a patient BC24 with
BBC (Table 4). The consequence of this mutation is a
truncated protein without NLC2 and 3 motifs at the C-
terminus.
Unclassified variants
In addition to the unequivocally damaging mutations, many
VUSs have been reported in index cases of high-risk BC/
OC families in the absence of pathogenic mutation, and
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be immediately inferred [46]. Classifying these variants of
unknown clinical significance as neutral or disease causing
is very important for the genetic counseling.
We have identified in total 50 VUSs in both genes: 24 in
BRCA1 and 26 in BRCA2, of which 24 were missense vari-
ants (Table 5). The in silico analysis suggested a possible
deleterious effect of only five missense variants with all pre-
diction programs (c.1067A >G, c.1648A >C and c.3113A >
G in BRCA1 and 3515C >T and c.6100C >T in BRCA2)
(Table 6). Another two: 139 T >G and c.536A >G in
BRCA1 appeared to be clinically important according to
POLYPHEN 2 and SIFT only (Table 6). One new BRCA1
missense variant c.3999 T >C was observed in a patient
BC20 with BBC and early onset in the absence of other
pathogenic mutations, but the in silico analysis did not pre-
dict a possible pathogenic effect (Table 6).
The variant c.139 T >G that appeared to be clinically im-
portant upon in silico analysis is colocalized with the mis-
sense mutation c.181T >G in the RING finger domain of
BRCA1 (exon 5) and has been recognized as one of the
zinc-coordinating residues of the protein [10]. It was re-
ported once in BIC database as a VUS [10]. Up to date
there is no information available about its allele frequencies
in different populations. Several functional studies have
suggested a pathogenic effect of c.139T >G since in cell
culture experiments it caused disability in coordination of
the zinc ions in the RING domain and abolished the ubi-
quitin ligase activity of BRCA1 protein as well as its partici-
pation in the homologous recombination and the control
of the centrosome number [25]. In our study the missense
variantc.139T >G was found in one patient (0.5 %) with
TNBC and early onset of the disease BC10, in the absence
of other pathogenic mutation. However in order to ascer-
tain its pathogenicity, further analysis of large genomic rear-
rangements in BRCA1/2 genes, as well as segregation
analysis in the family of the patient need to be performed.
For all other missense variants that were predicted
pathogenic by the in silico analysis (Table 6), the existing
information in the literature has been controversial. For
example, in some studies no association with BC has been
found for the BRCA1 VUS c.1067A >G (Q356R), although
the authors claimed that being homozygous for 356R
might protect against BC [46]. According to other predic-
tion models it demonstrated a possible harmful role [46].
Similar results have been obtained for the c.536A >G,
c.1648A > C, c.3113A >G in BRCA1 and 3515C > Tin
BRCA2 [46]. Functional studies suggested that c.536A >G
but not c.1648A > C variant might be related to BRCA1-
associated pathogenicity by affecting its function in non-
homologous end joining (NHEJ) [25].
In the present study c.536A > G and c.1648A > C in
BRCA1, as well as c.3515C > T in BRCA2 (Table 5) were
observed only in patients, with a low frequency (MAF <0.005). In contrast 1067A > G and c.3113A > G in
BRCA1 (Table 5) were detected in both patients and
controls with a high frequency (MAF > 0.005).
The c.536A > G, c.1456 T > C and c.1648A > C have
been often seen together and probably constitute a rare
haplotype [47]. One of these substitutions, c.1456T > C
was classified as neutral in the in silico analysis, in
contrast to the other two (Table 6). We have observed
this haplotype in one patient BC117 with family his-
tory of BC diagnosed at the age of 48. Her sister also
developed BC at the age of 42, and subsequently died
of the disease. We genotyped the patient’s healthy
daughter and the two healthy daughters of her sister.
One of the proband’s nieces was also carrier of the
three missense variants. Identical case was reported in
a Sicilian family where the proband with early onset of
BC, her mother with early onset of uterine cancer and
her healthy sister harboured the haplotype 536A > G,
c.1456T > C, c.1648A > C [47]. It has been suggested
that the three amino acid changes might alter the
charge and stoichiometry of the protein and in conse-
quence its function [47].
Even though the in silico analyses might assign dele-
terious function to some VUSs, they are not always con-
sistent with the biological evidences. Further functional
assays are necessary to prove the pathogenic effect of all
missense variants predicted to be deleterious in current
and previous studies.Conclusions
As a result of the present study a mutation profile of the
BRCA1/2 genes in Bulgarian BC/OC patients has been
established with 13 (11 frameshift, 1 nonsense, 1 mis-
sense) unequivocally disease causing mutations. Muta-
tions in BRCA1 gene were found in 14 % (28/200) and
in BRCA2 in 5.5 % (11/200) of the Bulgarian patients se-
lected by the recognized criteria for BRCA1/2 genetic test-
ing. Four new frameshift (2 in BRCA1 and 2 in BRCA2
genes) have been found. Altogether inherited BC predis-
position was identified in 39 (19.5 %) of the patients.
The most prevalent mutation in Eastern Europe
c.5263_5264insC appeared to have a founder effect in the
Bulgarian population with an overall frequency of 11 % in
the studied cohort of familial BC/OC patients. It was also
found in 14 % of the patients with TNBC without family
history. Together with the other 3 recurrent mutations
identified (c.181T >G in BRCA1; c.9098_9099insA and
c.5851_5854delAGTT in BRCA2) they account for 77 %
of all detected mutations. However, MLPA analysis is ne-
cessary to be performed in order to ascertain the contribu-
tion of the large genomic indels and rearrangements in
BRCA1/2 genes for familial BC/OC development in the
Bulgarian population.
Dodova et al. BMC Cancer  (2015) 15:523 Page 15 of 16Consequently, we suggest a mutation screening pipe-
line in which an initial test is performed to specifically
detect BRCA1 c.5263_5264insC and the 3 additional re-
current mutations in BC patients from severely affected
families to identify about two thirds of the carriers. In
the remaining patients without mutations, complete se-
quencing of the coding regions of BRCA1 and BRCA2 is
warranted, followed by MLPA screening. Such an ap-
proach would improve the effectiveness of the protocol
and reduce the costs of mutation screening. This may
have direct effect on the efficient molecular diagnostics
of the genetic predisposition to BC/OC in Bulgaria.
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